Clinical trialPhase 1 / Phase 2Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 27 May 2021
- Expected end
- 31 August 2031
- Enrollment
- 1,109 participants
- Sites
- 47
- Primary outcomes
- Incidence of adverse events (AEs); Incidence of serious adverse events (SAEs); Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria; Incidence of AEs leading to discontinuation; Number of deaths
- Sponsor
- Industry
- Results posted
- No
- Last update
- 17 August 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.